Journal of the American Society of Hypertension
Volume 3, Issue 6 , Pages 403-415, November 2009

Costs associated with cardiovascular events in patients with hypertension in US managed care settings

  • Mei Sheng Duh, MPH, ScD

      Affiliations

    • Analysis Group, Inc., Boston, Massachusetts, USA
    • Corresponding Author InformationCorresponding author: Mei Sheng Duh, MPH, ScD, Analysis Group, Inc., 111 Huntington Avenue, 10th Floor, Boston, Massachusetts 02199. Tel: 617-425-8131; fax: 617-425-8001.
  • ,
  • Nicole M. Fulcher, MA

      Affiliations

    • Analysis Group, Inc., Boston, Massachusetts, USA
  • ,
  • Leigh Ann White, PhD

      Affiliations

    • Analysis Group, Inc., Boston, Massachusetts, USA
  • ,
  • Sujata S. Jayawant, PhD

      Affiliations

    • Analysis Group, Inc., Boston, Massachusetts, USA
  • ,
  • Priyanka Ramamurthy, BA

      Affiliations

    • Analysis Group, Inc., Boston, Massachusetts, USA
  • ,
  • Erick Moyneur, MA

      Affiliations

    • Analysis Group, Inc., Boston, Massachusetts, USA
  • ,
  • Siew Hwa Ong, MSc

      Affiliations

    • Global Health Economics & Outcomes Research, Novartis Pharma AG, Basel, Switzerland

Received 12 June 2009; accepted 8 September 2009.

Abstract 

Study quantified incremental cost of cardiovascular (CV) events in 6 high-risk and compelling indication subgroups: post-myocardial infarction (MI), diabetes, diabetic nephropathy, elderly, chronic kidney disease, and prior stroke. Based on claims data from privately insured individuals with 2+ hypertension (HTN) diagnoses in 2004–2006, we estimated regression-adjusted per-member-per-month healthcare costs after CVE. Costs were compared between patients with and without a CV events, and before and after CV events in each subgroup. The following CVevents were studied: acute MI, acute coronary syndrome, angina, ventricular arrhythmia, atrial arrhythmia, heart failure, coronary artery disease, left ventricular hypertrophy, stroke, and sinus tachycardia. Of 1,598,890 HTN patients, 510,118 had ≥1 CV event. Compared with controls, healthcare costs among patients with events were significantly greater across all cost components (inpatient, outpatient, and prescription drug). Acute MI and congestive heart failure generally had the largest incremental total healthcare costs. First-quarter post-event costs were attributable to inpatient costs. CV events are costly sequelae of hypertension in high-risk and CI subgroups.

Keywords: Healthcare costs, outcome assessment (healthcare), hypertension, cardiovascular diseases

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This study was funded by Novartis Pharma AG, Basel, Switzerland. The results of the study were not contingent on the funding.

 Conflict of interest: none.

PII: S1933-1711(09)00106-5

doi:10.1016/j.jash.2009.09.001

Journal of the American Society of Hypertension
Volume 3, Issue 6 , Pages 403-415, November 2009